A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

Trimeris

Status and phase: Unknown; Phase 2; Phase 1

Conditions: HIV Infections

Treatments: Drug: T-1249

Study type: Interventional

Funder types: Industry

Identifiers

NCT00048217

T1249-105

Details and patient eligibility

About

Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Completion T1249-102;
• Currently failing a T-20 containing regimen

Exclusion criteria

• Non-completion of T1249-102.